EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan

Mitsunobu Otsuru iD, Souichi Yanamoto iD, Shin-Ichi Yamada, Kohichi Nakashiro iD, Yosuke Harazono iD, Tomoyuki Kohgo, Moriyoshi Nakamura, Takeshi Nomura, Atsushi Kasamatsu iD, Susumu Tanaka, Tadaaki Kirita iD, Mitomu Kioi und 4 weitere

International Journal of Environmental Research and Public Health · 2023

DOI: 10.3390/ijerph20054545 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Environmental Research and Public Health, 2023. Verfasst von Mitsunobu Otsuru und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Mouth Neoplasms, Head and Neck Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are a few reports that focus on radiotherapy (RT) and cetuximab (CET) therapy exclusively for oral cancer. This retrospective study aimed to investigate the efficacy and safety of RT and CET therapy for locally advanced (LA) or recurrent/metastatic (R/M) oral squamous cell carcinoma (OSCC). Seventy-nine patients from 13 hospitals who underwent RT and CET therapy for LA or R/M OSCC between January 2013 and May 2015 were enrolled in the study. Response, overall survival (OS), disease-specific survival (DSS), and adverse events were investigated. The completion rate was 62/79 (78.5%). The response rates in patients with LA and R/M OSCC were 69% and 37.8%, respectively. When only completed cases were examined, the response rates were 72.2% and 62.9%, respectively. The 1- and 2-year OS were 51.5% and 27.8%, respectively (median, 14 months), for patients with LA OSCC, and 41.5% and 11.9% (median, 10 months) for patients with R/M OSCC. The 1- and 2-year DSS were 61.8% and 33.4%, respectively (median, 17 months), for patients with LA OSCC, and 76.6% and 20.4% (median, 12 months) for patients with R/M OSCC. The most common adverse event was oral mucositis (60.8%), followed by dermatitis, acneiform rash, and paronychia. The completion rate was 85.7% in LA patients and 70.3% in R/M patients. The most common reason for noncompletion was an inadequate radiation dose due to worsening general conditions in R/M patients. Although the standard treatment for LA or R/M oral cancer is concomitant RT with high-dose cisplatin (CCRT) and the efficacy of RT and CET therapy for oral cancer is not considered to be as high as that for other head and neck cancers, it was thought that RT and CET therapy could be possible treatments for patients who cannot use high-dose cisplatin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellMouth NeoplasmsHead and Neck NeoplasmsHumansCetuximabCisplatinRetrospective StudiesJapanAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalSquamous Cell Carcinoma of Head and Neck

Stichwörter der Autor:innen

chemotherapymulticenter studyoral cancerprognosis

Substanzen

CetuximabCisplatin

Autor:innen und Institutionen

  • Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan.
  • Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
  • Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
  • Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan.
  • Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Ehime 791-0295, Japan.
  • Department of Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8549, Japan.

ORCID-Profile: Mitsunobu Otsuru, Souichi Yanamoto, Kohichi Nakashiro, Yosuke Harazono, Atsushi Kasamatsu, Tadaaki Kirita

Zitieren

APA

Otsuru, M., Yanamoto, S., Yamada, S. I., Nakashiro, K., Harazono, Y., Kohgo, T., Nakamura, M., Nomura, T., Kasamatsu, A., Tanaka, S., Kirita, T., Kioi, M., Ogawa, M., Sasaki, M., Ota, Y., & Umeda, M. (2023). Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph20054545

Vancouver

Otsuru M, Yanamoto S, Yamada SI, Nakashiro K, Harazono Y, Kohgo T, et al. Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan. International Journal of Environmental Research and Public Health. 2023. doi:10.3390/ijerph20054545

BibTeX
@article{Otsuru2023,
  author = {Otsuru, Mitsunobu and Yanamoto, Souichi and Yamada, Shin-Ichi and Nakashiro, Kohichi and Harazono, Yosuke and Kohgo, Tomoyuki and Nakamura, Moriyoshi and Nomura, Takeshi and Kasamatsu, Atsushi and Tanaka, Susumu and Kirita, Tadaaki and Kioi, Mitomu and Ogawa, Masaru and Sasaki, Masashi and Ota, Yoshihide and Umeda, Masahiro},
  title = {Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan},
  journal = {International Journal of Environmental Research and Public Health},
  year = {2023},
  doi = {10.3390/ijerph20054545}
}
Kostenlos starten →